SWOT Analysis for Norris Medicines Ltd.

Positive Breakout First Resistance ( LTP > R1)
Consistent Highest Return Stocks over Five Years
Rising Net Cash Flow and Cash from Operating activity
Relative Outperformance versus Industry over 1 Year
Relative Outperformance versus Industry over 1 Week
Growth in Net Profit with increasing Profit Margin (QoQ)
Increasing profits every quarter for the past 3 quarters
Company able to generate Net Cash - Improving Net Cash Flow for last 2 years
Companies with Zero Promoter Pledge
Stock with Low PE (PE < = 10)
Stocks in uptrend most likely to cross above SMA-200 soon
Top Gainers

PEG greater than Industry PEG
Bearish Stocks - Stocks with Medium to Low Trendlyne Momentum Score
Stocks with Expensive Valuations according to the Trendlyne Valuation Score
Inefficient use of capital to generate profits - RoCE declining in the last 2 years
Low Piotroski Score : Companies with weak financials
Book Value Per Share deteriorating for last 2 years
Weak Momentum: Price below Short, Medium and Long Term Averages
Increasing Trend in Non-Core Income
RSI indicating price weakness
Declining profitability: Falling ROCE
Stocks Underperforming their Industry Price Change in the Quarter